Sanofi ADS (SNY)
SNY trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | SNY on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | France |
| IPO year | Not reported by the screener |
| SEC CIK | 0001121404 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | France |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-02-17 |
| Cash and burn | 7.7B EUR cash; operating cash flow 2.7B EUR a quarter. | Report 2025-12-31 |
| Shares outstanding | 2,438,854,192 (2025-12-31); 2,526,245,442 a year earlier; 2,521,671,464 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Forvis Mazars SA, Levallois-Perret, France | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | 2 NT notices | NT 11-K 2026-06-30 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | 7.8B EUR | 10.8B EUR | 7.7B EUR | 18.7B EUR | Needs four quarters | 20-F 2026-02-17 |
| FY 2024 2024-12-31 | Not filed | 5.6B EUR | 9.1B EUR | 7.4B EUR | 16.1B EUR | Needs four quarters | 20-F 2026-02-17 |
| FY 2023 2023-12-31 | Not filed | 5.4B EUR | 10.3B EUR | 8.7B EUR | 16.5B EUR | Needs four quarters | 20-F 2026-02-17 |
| FY 2022 2022-12-31 | Not filed | 8.4B EUR | 10.5B EUR | 12.7B EUR | 19.2B EUR | Needs four quarters | 20-F 2025-02-13 |
| FY 2021 2021-12-31 | Not filed | 6.2B EUR | 10.5B EUR | 10.1B EUR | 20.3B EUR | Needs four quarters | 20-F 2024-02-23 |
| FY 2020 2020-12-31 | Not filed | 12.3B EUR | 7.4B EUR | 13.9B EUR | 22.6B EUR | Needs four quarters | 20-F 2023-02-24 |
| FY 2019 2019-12-31 | Not filed | 2.8B EUR | 7.7B EUR | 9.4B EUR | 24.6B EUR | Needs four quarters | 20-F 2022-02-23 |
| FY 2018 2018-12-31 | Not filed | 4.3B EUR | 5.5B EUR | 6.9B EUR | 24.6B EUR | Needs four quarters | 20-F 2021-03-04 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-10-29 |
| Latest annual report | 20-F | 2026-02-17 |
| Latest quarterly / interim | 6-K | 2026-10-30 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.8% |
| 1 month | +23.6% |
| 3 months | +10.5% |
| Year to date | -0.2% |
| 1 year | -7.6% |
| From 52-week high | -7.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | $62.93 | -0.79% | $128.6B |
| VRTX | Vertex Pharmaceuticals Incorporated | $537.79 | -0.15% | $136.4B |
| GSK | GSK plc | $50.41 | -0.08% | $102.0B |
| REGN | Regeneron Pharmaceuticals Inc. | $952.40 | -0.32% | $98.5B |
| PFE | Pfizer Inc. | $28.86 | -0.10% | $164.5B |
| NVO | Novo Nordisk A/S | $41.60 | -0.07% | $184.2B |
| ABT | Abbott Laboratories | $107.45 | -0.99% | $186.1B |
| TAK | Takeda Pharmaceutical Company Limited | $21.59 | +0.75% | $68.2B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier